Gladius Capital Management LP Takes $36,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Gladius Capital Management LP bought a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 1,098 shares of the biotechnology company’s stock, valued at approximately $36,000.

A number of other large investors also recently modified their holdings of CORT. Boston Trust Walden Corp boosted its position in shares of Corcept Therapeutics by 1.1% during the fourth quarter. Boston Trust Walden Corp now owns 1,846,924 shares of the biotechnology company’s stock valued at $59,988,000 after buying an additional 19,877 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Corcept Therapeutics by 4.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 900,444 shares of the biotechnology company’s stock worth $29,246,000 after purchasing an additional 39,111 shares during the last quarter. FMR LLC grew its position in Corcept Therapeutics by 102.4% in the 3rd quarter. FMR LLC now owns 683,924 shares of the biotechnology company’s stock worth $18,634,000 after purchasing an additional 346,000 shares in the last quarter. Burney Co. increased its stake in Corcept Therapeutics by 40.2% in the 3rd quarter. Burney Co. now owns 401,263 shares of the biotechnology company’s stock valued at $10,932,000 after buying an additional 115,006 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Corcept Therapeutics by 996.5% during the 3rd quarter. Acadian Asset Management LLC now owns 318,027 shares of the biotechnology company’s stock worth $8,653,000 after buying an additional 289,023 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Insider Activity at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $23.59, for a total value of $51,898.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $23.59, for a total transaction of $51,898.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Joseph Douglas Lyon sold 10,830 shares of Corcept Therapeutics stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $26.00, for a total value of $281,580.00. Following the transaction, the insider now directly owns 7,314 shares of the company’s stock, valued at approximately $190,164. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,413 shares of company stock worth $2,352,176. 20.50% of the stock is owned by corporate insiders.

Corcept Therapeutics Stock Performance

NASDAQ:CORT traded up $1.20 during trading hours on Thursday, reaching $26.60. The stock had a trading volume of 1,265,816 shares, compared to its average volume of 1,457,347. The stock has a market cap of $2.77 billion, a P/E ratio of 25.09 and a beta of 0.50. The stock has a 50 day simple moving average of $24.09 and a 200 day simple moving average of $25.14. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $34.28.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.04. The company had revenue of $146.80 million during the quarter, compared to the consensus estimate of $141.19 million. Corcept Therapeutics had a return on equity of 24.19% and a net margin of 22.38%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.14 EPS. On average, equities analysts expect that Corcept Therapeutics Incorporated will post 0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CORT has been the subject of a number of research analyst reports. HC Wainwright increased their price target on Corcept Therapeutics from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 3rd. Finally, Truist Financial boosted their price target on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $40.10.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.